Cipher Pharmaceuticals$CPH

16 research articles

Cipher Pharmaceuticals ($CPH) has 16 independent research articles on RhinoInvestory, written by 3 independent analysts covering the Health Care sector in Canada.

Health Care Canada

Analysts Covering Cipher Pharmaceuticals

Leftfield Investing (8)Divergent Capital 7651 (7)Planet MicroCap

Research Articles

Q1'26 Idea Inventory, Part 1: $CPH.TO, $RCI.B, $SNAP, $HON.

By Divergent Capital 7651 • 2026-02-18T05:22:24.868Z

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF): Specialty Pharmaceuticals Focused on Dermatology Products

By Planet MicroCap • 2024-08-21T13:01:49.873Z

UPDATE: Cipher Pharmaceuticals - Incidental discovery involving piclidenoson in pre-clinical studies for the treatment of Lowe Syndrome

By Leftfield Investing • 2023-11-04T15:03:45.706Z

Cipher Pharmaceuticals - Piclidenoson

By Leftfield Investing • 2023-12-05T03:44:03.249Z

UPDATE: Cipher Pharmaceuticals - Sun Pharmaceuticals has officially begun marketing of Absorica LD in Canada as of early December

By Leftfield Investing • 2023-12-23T14:19:29.562Z

UPDATE: Cipher Pharmaceuticals - Incidental discovery involving piclidenoson in pre-clinical studies for the treatment of Lowe Syndrome

By Leftfield Investing • 2023-11-04T15:03:45.706Z

Cipher Pharmaceuticals - Piclidenoson

By Leftfield Investing • 2023-12-05T03:44:03.249Z

UPDATE: Cipher Pharmaceuticals - Sun Pharmaceuticals has officially begun marketing of Absorica LD in Canada as of early December

By Leftfield Investing • 2023-12-23T14:19:29.562Z

Just look at Cipher Pharmaceuticals

By Leftfield Investing • 2025-06-18T03:15:45.297Z

Just look at Cipher Pharmaceuticals

By Leftfield Investing • 2025-06-18T03:15:45.297Z

Cipher Pharmaceuticals: Write-Up Preview

By Divergent Capital 7651 • 2024-05-13T02:44:45.553Z

Cipher Pharmaceuticals: A High ROIC Legacy Business at a Fair Price with a Free Call-Option on Two Unpriced Catalysts

By Divergent Capital 7651 • 2024-05-19T23:17:37.185Z

Cipher Pharmaceuticals: Write-Up Preview

By Divergent Capital 7651 • 2024-05-13T02:44:45.553Z

Cipher Pharmaceuticals: A High ROIC Legacy Business at a Fair Price with a Free Call-Option on Two Unpriced Catalysts

By Divergent Capital 7651 • 2024-05-19T23:17:37.185Z

Estimate of Cipher Pharmaceuticals' Potential Future Operating Income Post-Natroba Acquisition.

By Divergent Capital 7651 • 2024-08-12T06:12:42.092Z

Notes from Cipher Pharmaceuticals' Planet Microcap Interview dated 21 August 2024.

By Divergent Capital 7651 • 2024-08-22T07:12:04.003Z